logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Severe Pain

    FiltersReset Filters
    19 results

    • belbuca

      (buprenorphine hydrochloride)
      BioDelivery Sciences International Inc
      Usage: BELBUCA is indicated for the management of severe and persistent pain requiring long-term opioid treatment when alternative options are inadequate. It is not recommended for as-needed use and should be reserved for patients for whom other treatments have failed or are unsuitable.

    • buprenorphine hydrochloride

      (Buprenorphine Hydrochloride)
      ENDO USA, Inc.
      Usage: Buprenorphine hydrochloride injection is indicated for managing severe pain requiring an opioid analgesic when alternative treatments are inadequate. It should be reserved for patients who cannot tolerate non-opioid options or when those options fail to provide sufficient pain relief.

    • buprenorphine hydrochloride

      (Buprenorphine Hydrochloride)
      Hospira, Inc.
      Usage: Buprenorphine hydrochloride injection is indicated for managing severe pain that requires an opioid analgesic when alternative treatments are inadequate. It is reserved for cases where non-opioid options are intolerable or ineffective, and should not be used long-term unless pain severity persists.

    • butorphanol tartrate

      (Butorphanol Tartrate)
      Hikma Pharmaceuticals USA Inc.
      Usage: Butorphanol Tartrate Nasal Spray is indicated for managing severe pain requiring opioid analgesics when alternative treatments are inadequate. It should be used with caution due to risks of addiction, abuse, and misuse, and only when other pain relief options have failed or are intolerable.

    • fentanyl

      (FENTANYL)
      Mylan Pharmaceuticals Inc.
      Usage: The fentanyl transdermal system is indicated for managing severe, persistent pain in opioid-tolerant patients requiring long-term opioid treatment when other options are inadequate. It is not intended for as-needed use and carries risks of addiction, abuse, and overdose.

    • fentanyl system

      (Fentanyl)
      ALVOGEN
      Usage: Fentanyl transdermal system is indicated for managing severe, persistent pain in opioid-tolerant patients requiring long-term opioid therapy, when other treatments are insufficient. It is not meant for as-needed use. Caution is advised due to risks of addiction, abuse, and overdose.

    • hydromorphone hydrochloride

      (HYDROMORPHONE HYDROCHLORIDE)
      Hospira, Inc.
      Usage: Hydromorphone Hydrochloride Injection is indicated for managing severe pain when alternative treatments are inadequate. It should be reserved for patients intolerant to or not benefiting from non-opioid analgesics, with caution due to risks of addiction, abuse, and misuse associated with opioid use.

    • hydromorphone hydrochloride

      (Hydromorphone Hydrochloride)
      Trigen Laboratories, LLC
      Usage: Hydromorphone hydrochloride extended-release tablets are indicated for managing severe, persistent pain requiring long-term opioid treatment when alternative options are inadequate. They are not intended for as-needed use and are reserved for opioid-tolerant patients due to risks of addiction, abuse, and overdose.

    • hysingla er

      (hydrocodone bitartrate)
      Purdue Pharma LP
      Usage: HYSINGLA ER is indicated for managing severe, persistent pain requiring long-term opioid treatment when other options are insufficient. It should be reserved for patients unsuitable for non-opioid analgesics or immediate-release opioids due to risks of addiction, abuse, and overdose. It is not for as-needed use.

    • methadone hydrochloride

      (METHADONE HYDROCHLORIDE)
      SpecGx LLC
      Usage: Methadone hydrochloride tablets are indicated for managing severe, persistent pain requiring long-term opioid treatment, and for detoxification and maintenance treatment of opioid addiction. They are not meant for as-needed pain relief and should only be used when other options are inadequate.